Literature DB >> 15908392

Characterization of fluorescent chimeras of cholera toxin and Escherichia coli heat-labile enterotoxins produced by use of the twin arginine translocation system.

Juliette K Tinker1, Jarrod L Erbe, Randall K Holmes.   

Abstract

Cholera toxin (CT) is an AB(5) toxin responsible for the profuse secretory diarrhea resulting from Vibrio cholerae infection. CT consists of a pentameric, receptor-binding B subunit (CTB) and a monomeric A subunit (CTA) that has latent enzymatic activity. In addition to its enterotoxicity, CT has potent mucosal adjuvant activity and can also function as a carrier molecule with many potential applications in cell biology. In earlier studies, the toxic CTA(1) domain was replaced by several other antigenic protein domains to produce holotoxin-like chimeras for use as potential mucosal vaccines. In the present study we utilized the twin arginine translocation (tat) system to produce fluorescent CT chimeras, as well as fluorescent chimeras of Escherichia coli heat-labile toxins LTI and LTIIb. Fusion proteins containing either green fluorescent protein (GFP) or monomeric red fluorescent protein (mRFP) and the A(2) domain of CT, LTI, or LTIIb were transported to the periplasm of E. coli by the tat system, and the corresponding B polypeptides of CT, LTI, and LTIIb were transported to the periplasm by the sec system. The fluorescent fusion proteins were shown to assemble spontaneously and efficiently with the corresponding B polypeptides in the periplasm to form chimeric holotoxin-like molecules, and these chimeras bound to and entered cultured cells in a manner similar to native CT, LTI, or LTIIb. The GFP and mRFP derivatives of CT, LT, and LTIIb developed here are useful tools for studies on the cell biology of trafficking of the CT/LT family of bacterial enterotoxins. In addition, these constructs provide proof in principle for the development of novel chimeric CT-like or LT-like vaccine candidates containing CTA(2) fusion proteins that cannot be delivered to the periplasm of E. coli by use of the sec secretion pathway.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15908392      PMCID: PMC1111858          DOI: 10.1128/IAI.73.6.3627-3635.2005

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  44 in total

1.  Use of translational fusion of the MrpH fimbrial adhesin-binding domain with the cholera toxin A2 domain, coexpressed with the cholera toxin B subunit, as an intranasal vaccine to prevent experimental urinary tract infection by Proteus mirabilis.

Authors:  Xin Li; Jarrod L Erbe; C Virginia Lockatell; David E Johnson; Michael G Jobling; Randall K Holmes; Harry L T Mobley
Journal:  Infect Immun       Date:  2004-12       Impact factor: 3.441

2.  Oral immunization with the saliva-binding region of Streptococcus mutans AgI/II genetically coupled to the cholera toxin B subunit elicits T-helper-cell responses in gut-associated lymphoid tissues.

Authors:  N Toida; G Hajishengallis; H Y Wu; M W Russell
Journal:  Infect Immun       Date:  1997-03       Impact factor: 3.441

3.  Temperature dependence of endocytosis in renal epithelial cells in culture.

Authors:  Z Mamdouh; M C Giocondi; R Laprade; C Le Grimellec
Journal:  Biochim Biophys Acta       Date:  1996-07-25

Review 4.  Accumulating evidence suggests that several AB-toxins subvert the endoplasmic reticulum-associated protein degradation pathway to enter target cells.

Authors:  B Hazes; R J Read
Journal:  Biochemistry       Date:  1997-09-16       Impact factor: 3.162

5.  A novel and ubiquitous system for membrane targeting and secretion of cofactor-containing proteins.

Authors:  J H Weiner; P T Bilous; G M Shaw; S P Lubitz; L Frost; G H Thomas; J A Cole; R J Turner
Journal:  Cell       Date:  1998-04-03       Impact factor: 41.582

6.  Mucosal immunogenicity of a holotoxin-like molecule containing the serine-rich Entamoeba histolytica protein (SREHP) fused to the A2 domain of cholera toxin.

Authors:  F Sultan; L L Jin; M G Jobling; R K Holmes; S L Stanley
Journal:  Infect Immun       Date:  1998-02       Impact factor: 3.441

7.  Imaging the intracellular trafficking and state of the AB5 quaternary structure of cholera toxin.

Authors:  P I Bastiaens; I V Majoul; P J Verveer; H D Söling; T M Jovin
Journal:  EMBO J       Date:  1996-08-15       Impact factor: 11.598

8.  Proteolytic activation of cholera toxin and Escherichia coli labile toxin by entry into host epithelial cells. Signal transduction by a protease-resistant toxin variant.

Authors:  W I Lencer; C Constable; S Moe; P A Rufo; A Wolf; M G Jobling; S P Ruston; J L Madara; R K Holmes; T R Hirst
Journal:  J Biol Chem       Date:  1997-06-13       Impact factor: 5.157

Review 9.  Membrane traffic and the cellular uptake of cholera toxin.

Authors:  W I Lencer; T R Hirst; R K Holmes
Journal:  Biochim Biophys Acta       Date:  1999-07-08

10.  Construction and characterization of versatile cloning vectors for efficient delivery of native foreign proteins to the periplasm of Escherichia coli.

Authors:  M G Jobling; L M Palmer; J L Erbe; R K Holmes
Journal:  Plasmid       Date:  1997       Impact factor: 3.466

View more
  14 in total

1.  Purification and characterization of Yersinia enterocolitica and Yersinia pestis LcrV-cholera toxin A(2)/B chimeras.

Authors:  Juliette K Tinker; Chadwick T Davis; Britni M Arlian
Journal:  Protein Expr Purif       Date:  2010-05-11       Impact factor: 1.650

Review 2.  The bacterial twin-arginine translocation pathway.

Authors:  Philip A Lee; Danielle Tullman-Ercek; George Georgiou
Journal:  Annu Rev Microbiol       Date:  2006       Impact factor: 15.500

Review 3.  Production of active eukaryotic proteins through bacterial expression systems: a review of the existing biotechnology strategies.

Authors:  Sudhir Sahdev; Sunil K Khattar; Kulvinder Singh Saini
Journal:  Mol Cell Biochem       Date:  2007-09-12       Impact factor: 3.396

4.  Type II secretion system secretin PulD localizes in clusters in the Escherichia coli outer membrane.

Authors:  Nienke Buddelmeijer; Martin Krehenbrink; Frédéric Pecorari; Anthony P Pugsley
Journal:  J Bacteriol       Date:  2008-10-31       Impact factor: 3.490

5.  Mucosal immunization with a Staphylococcus aureus IsdA-cholera toxin A2/B chimera induces antigen-specific Th2-type responses in mice.

Authors:  Britni M Arlian; Juliette K Tinker
Journal:  Clin Vaccine Immunol       Date:  2011-07-06

6.  Functional analysis of the twin-arginine translocation pathway in Corynebacterium glutamicum ATCC 13869.

Authors:  Yoshimi Kikuchi; Masayo Date; Hiroshi Itaya; Kazuhiko Matsui; Long-Fei Wu
Journal:  Appl Environ Microbiol       Date:  2006-09-22       Impact factor: 4.792

7.  Immunogenicity of a Staphylococcus aureus-cholera toxin A2/B vaccine for bovine mastitis.

Authors:  N Misra; T F Wines; C L Knopp; R Hermann; L Bond; B Mitchell; M A McGuire; J K Tinker
Journal:  Vaccine       Date:  2018-05-05       Impact factor: 3.641

8.  In-Depth Characterization of a Re-Engineered Cholera Toxin Manufacturing Process Using Growth-Decoupled Production in Escherichia coli.

Authors:  Natalia Danielewicz; Wenyue Dai; Francesca Rosato; Michael E Webb; Gerald Striedner; Winfried Römer; W Bruce Turnbull; Juergen Mairhofer
Journal:  Toxins (Basel)       Date:  2022-06-08       Impact factor: 5.075

9.  Cholera toxin subunit B peptide fusion proteins reveal impaired oral tolerance induction in diabetes-prone but not in diabetes-resistant mice.

Authors:  Maximiliano Presa; Angela Zarama Ortiz; Nahir Garabatos; Cristina Izquierdo; Elisa I Rivas; Luc Teyton; Conchi Mora; David Serreze; Thomas Stratmann
Journal:  Eur J Immunol       Date:  2013-08-27       Impact factor: 5.532

Review 10.  Cholera Toxin Subunit B as Adjuvant--An Accelerator in Protective Immunity and a Break in Autoimmunity.

Authors:  Thomas Stratmann
Journal:  Vaccines (Basel)       Date:  2015-07-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.